Skip to main content
OpenTrials
Completed

NCT Number: NCT02632825

Effects of Nasal High Flow Therapy on Ventilation and Gas Exchange in Healthy Newborns

Nasal High Flow (NHF) and CPAP are established forms of respiratory support in neonates and often produce similar clinical outcomes. It has been shown in adults that NHF produce different effects on ventilation during wakefulness and sleep. There is no physiological data on effects of NHF in neonates. The physiological effects may be impacted by sleep/awake status.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

1 day–3 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Neonatal Intensive Care Unit, Research Centre of Maternal and Child Health

Yerevan, 0002, Armenia

About this study

The aim of the study to investigate the effects of NHF therapy on ventilation and gas exchange during wakefulness and sleep in healthy term newborns.

Interventions:

NHF will be applied at 8 L/min (AIRVO 2) via (OPT 316) Optiflow nasal cannula interface without supplemental oxygen. Participants will act as their own control (no intervention) in a randomized crossover study design.

Physiological measurements:

  • Ventilation will be assessed using Respiratory Inductance Plethysmography (RIP) (Respitrace QDC, Viasys, USA).
  • Blood carbon dioxide (CO2) and oxygen levels will be measured by a non-invasive transcutaneous monitor (Tosca, Radiometer, Demnark).
  • All experiment will be recorded using Analogue-to-Digital converter (Powerlab, ADInstruments, New Zealand) and LabChart software with video recording of the patient.
  • Sleep/awake statuss will be determined by videorecording of the patient and Electroencephalogram (EEG) (Alice Polysomnography System Philips, USA)
  • The total study time will be <3 hours in total for each participant. Routine measurement of heart rate, respiratory rate and oxygen saturation will be performed as per standard neonatal clinical practice.
  • Intervention can be terminated if at any time SpO2 drops below 80%, TcCO2 increases above 60 mm Hg, Respiratory Rate increases above 80 breaths per min for more than one minute).

The researcher is an experienced neonatal consultant will be conducting the research and observing the baby throughout the study.

Protocol:

Both control and NHF intervention periods will last a maximum of 40 min each. The maximum duration of the study including set-up, calibration, intervention, washout ans control will be <3 hours. At the beginning of the study when all probes are attached a self-calibration period of RIP will be followed by a calibration of breathing volume with a pneumotachometer attached to a nasal mask. After all calibrations are completed a baseline measurement will be followed by either NHF 8 L/min or a control period without NHF. At the end of this period the interventions will be changes either to control or NHF, which will follow by a washout period (no NHF) and an additional calibration of RIP with a pneumotachometer.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy full or near full-term newborns of 1-2 days of age.
  • A parent has given written informed consent to their baby's participation.

Exclusion criteria

  • Infants who are clinically unstable and unsuitable for non-invasive respiratory support as judged by consultant clinician or required supplemental oxygen.
  • Known upper airway, lower respiratory tract, cardiac or gastrointestinal tract anomaly.
  • A parent has not given written informed consent.

Treatment and study plan

Nasal High Flow

Device

Nasal High Flow Therapy

Primary outcomes

  1. Change of minute ventilation

    Time frame: Up to 1 hour

    Change of minute ventilation measured with calibrated Respiratory Inductance Plethysmography

  2. Change of respiratory rate

    Time frame: Up to 1 hour

    Change of respiratory rate measured with Respiratory Inductance Plethysmography

Secondary outcomes

  1. Tissue carbon dioxide

    Time frame: Up to 1 hour

    Change of transcutaneous tissue carbon dioxide

  2. Tissue oxygen

    Time frame: Up to 1 hour

    Change of transcutaneous oxygen

  3. Oxygen saturation

    Time frame: Up to 1 hour

    SpO2

  4. Heart rate

    Time frame: Up to 1 hour

    Heart rate measured with pulseoximeter

Sponsors and collaborators

Lead sponsor

Research Center of Maternal and Child Health Protection, Armenia

Other

Collaborators

  • Fisher and Paykel Healthcare

Registry information

Official study title

Effects of Nasal High Flow Therapy on Ventilation and Gas Exchange During Wakefulness and Sleep in Healthy Newborn Babies in a Randomized Crossover Study Design

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Dec 17, 2015
Registry last updated
Oct 31, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.